PERRIGO COMPANY PLC (PRGO) — 分析摘要
PERRIGO COMPANY PLC（PRGO）的市值为1.48十亿美元，最近一年的营收同比增长了-2.8%。净利润率为-33.5%。当前市盈率为-0.8倍。
核心要点
- 营收同比变化-2.8%
- 净利润率-33.5%
- 市盈率-0.8倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，PRGO的营收增长为-2.8%，市盈率为-0.8倍。
PERRIGO COMPANY PLC (PRGO)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示重点关注
当前存在需要关注的风险信号，应与估值结果一并解读。
营业利润率为 -36.9% — 经营亏损显著
净利率为 -43.5% — 亏损显著
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
8,100
总部
DUBLIN 2, L2
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$1.16
股息收益率
10.76%
股息历史
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。